Indian Pharmaceutical Supplier to Dominican Republic

Yes. DGDF — Dirección General de Drogas y Farmacias within MISPAS — accepts CDSCO Certificate of Pharmaceutical Product (CoPP) as part of the foreign-manufacturer recognition pack, alongside WHO-GMP certification of the Indian manufacturing site. This makes the regulatory pathway from India to the Dominican Republic procedurally cleaner than markets that require their own foreign-site inspection. The DGDF dossier still requires substantive Module 3 quality data, bioequivalence evidence for generic molecules, and stability data structured to Caribbean climatic-zone conventions, but the foreign-manufacturer recognition layer is workable on standard CDSCO and WHO-GMP documentation.

Sea freight predominantly routes through Puerto de Caucedo on the south coast, the Caribbean's principal hub port for containerised pharmaceutical traffic, with onward re-export potential to Haiti, Jamaica, and other Caribbean markets where the Dominican importer holds distribution rights. Puerto de Haina serves as a secondary Atlantic option and Santo Domingo's general port handles smaller consignments. For air freight and cold-chain, we route Mumbai to Las Américas International (SDQ) Santo Domingo. Routing is confirmed at order acceptance based on the importer's DGDF-licensed warehousing location and any Caribbean re-export geography.

PROMESE/CAL — Programa de Medicamentos Esenciales / Central de Apoyo Logístico — is the central pharmaceutical procurement and logistics agency for the public-health network in the Dominican Republic. PROMESE/CAL runs consolidated tenders for essential medicines distributed through MISPAS-affiliated hospitals and clinics. Procurement cycles are typically annual with quarterly delivery scheduling, and Dominican importers winning PROMESE/CAL contracts need supply partners who can hold pricing and meet quarterly delivery commitments. We structure our PROMESE/CAL-aligned supply with multi-quarter volume visibility and consignment scheduling that matches the agency's distribution rhythm.

Yes. DGDF requires Module 1 administrative content, the patient leaflet (prospecto), labelling, and the bulk of Module 3 quality documentation in Spanish, in CTD format aligned to DGDF conventions. Dominican Spanish regulatory phrasing has terminology specifics that differ from Mexican or Castilian Spanish, and we work with translation specialists familiar with Dominican pharmaceutical regulatory language rather than treating Spanish as a monolithic translation requirement. Original analytical certificates and selected reference documents may be accepted in English with Spanish summary, but the substantive dossier is Spanish.

Yes, where the Dominican importer holds regional distribution rights. Puerto de Caucedo's hub-port status, the dollarised commercial environment that prevails across much of the Caribbean basin, and the Dominican Republic's pharmaceutical regulatory infrastructure make it a workable consolidation point for onward distribution to Haiti, Jamaica, and selected smaller Caribbean markets. We structure documentation, packaging, and commercial paperwork to support that re-export logic where it applies, including separate import-of-record handling for the destination market and chain-of-custody documentation across the Caribbean leg.

International commercial invoicing is in USD, which suits Dominican commercial transactions where USD use is widespread alongside the Dominican Peso (DOP). The DOP is convertible and Dominican banking infrastructure handles pharmaceutical import documentation cleanly. Standard initial terms are letter of credit at sight or documents-against-payment, transitioning to open account on negotiated terms once a relationship is established and three to four consignments have cleared. For PROMESE/CAL-aligned supply, we accommodate the importer's tender-award payment cycles through structured commercial terms that match quarterly delivery scheduling.

We focus on anti-infectives — antibiotics, antivirals, antitubercular molecules — where PROMESE/CAL volume and private-channel demand both draw on Indian-origin supply for landed-cost efficiency. Cardiovascular generics, oncology orals and biosimilars, biological cold-chain, and diabetes care form the next pillars, distributed across PROMESE/CAL public-network supply and CARMI and Carol private-channel retail. We do not chase commodity OTC categories where Dominican domestic production competes effectively. Our therapeutic positioning is calibrated to where Indian supply genuinely improves landed economics for the Dominican payer system without compromising documentation discipline.